Context: To date only 18 patients with aggressive pituitary tumors or carcinomas treated
with temozolomide have been reported. Increased expression of O6-methylguanine-DNA-…

Background Dopamine agonist resistance in prolactinoma is an infrequent phenomenon.
Doses of cabergoline (CAB) of up to 2.0 mg/week are usually effective in controlling prolactin (…

Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin
analog 90 Y-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA)-d-Phe 1 …

Background Corticotropin-independent macronodular adrenal hyperplasia may be an
incidental finding or it may be identified during evaluation for Cushing's syndrome. Reports of …

Background Refractory hypoglycemia in patients with metastatic insulinoma is an important
cause of morbidity and mortality. Everolimus could be a new therapeutic option. Methods …

Primary liver cancers (ie hepatocellular carcinoma or cholangiocarcinoma) are worldwide
some of the most frequent cancers, with rapidly fatal liver failure in a large majority of patients. …

The management of cancer patients has changed due to the considerably more frequent use
of immune checkpoint inhibitors (ICPIs). However, the use of ICPI has a risk of side effects, …

Background Most pituitary neuroendocrine tumors (PitNETs) show benign behavior, but a
substantial number are invasive, recur, or resist medical treatment. Based on a retrospective …

The challenge for internal therapy is to deliver the highest possible dose to the tumor while
sparing normal organs from damage. Currently, the potential risk of kidney and red marrow …

Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs
in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and …